8-K: Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2024 Financial Results, Announces MilliporeSigma Collaboration

Rapid Micro Biosystems (RPID) announces strong Q4 and full-year 2024 results, driven by revenue growth and improved gross margins, and unveils a global distribution agreement with MilliporeSigma.

Summary

• Rapid Micro Biosystems reported a 30% increase in total revenue for Q4 2024, reaching $8.2 million, compared to $6.3 million in Q4 2023.
• Full-year 2024 total revenue grew by 25% to $28.1 million, up from $22.5 million in 2023.
• The company achieved a record gross margin of 12% in Q4 2024, a 15-percentage point improvement year-over-year.
• Full-year 2024 gross margin improved significantly to 0% compared to -24% in 2023.
• Net loss for Q4 2024 was $9.7 million, an improvement from the $11.2 million loss in Q4 2023.
• The net loss for the full year 2024 was $46.9 million, compared to $52.5 million in 2023.
• Rapid Micro Biosystems placed 6 Growth Direct systems and validated 4 customer systems in Q4 2024.
• For the full year, the company placed 21 Growth Direct systems and validated 16 customer systems, bringing the cumulative totals to 162 and 137, respectively.
• The company expects total revenue of at least $32.0 million in 2025, with 21 to 25 system placements.
• A global Distribution and Collaboration Agreement with MilliporeSigma was announced, granting them co-exclusive rights to sell Growth Direct systems and related consumables.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, improved gross margins, and a strategic collaboration, but tempered by the continued net losses.

Positives

• Significant revenue growth in both Q4 and full-year 2024.
• Substantial improvement in gross margins.
• Decrease in operating expenses.
• Reduction in net loss compared to the previous year.
• Strategic collaboration with MilliporeSigma to expand market reach.
• Increase in system placements and validations.

Negatives

• The company still reported a net loss for both Q4 and the full year 2024.
• Total cost of revenue increased slightly for the full year 2024.

Risks

• The company's ability to meet its revenue guidance for 2025.
• The effectiveness of the collaboration with MilliporeSigma.
• Competition within the automated microbial quality control testing industry.
• Potential supply chain disruptions and the impact of inflation.
• Macroeconomic volatility affecting the company's business and operations.

Future Outlook

The company expects total revenue of at least $32.0 million in 2025, with 21 to 25 system placements.

Management Comments

• Robert Spignesi, President and CEO, stated that the company is pleased with the record fourth-quarter sales and gross margin performance.
• Management expects to build on this momentum in 2025 through continued focus on strategic priorities.
• Management is excited about the global Distribution and Collaboration Agreement with MilliporeSigma and expects it to accelerate progress against strategic priorities.

Industry Context

This announcement reflects a growing trend in the life sciences industry towards automation and improved quality control processes, with companies like Rapid Micro Biosystems providing solutions to meet these needs.

Comparison to Industry Standards

• Given the limited information, a direct comparison to industry standards is difficult.
• However, companies like Danaher and Thermo Fisher Scientific, which also operate in the life sciences and diagnostics space, often report higher gross margins, suggesting that Rapid Micro Biosystems has room for improvement in this area.
• The collaboration with MilliporeSigma is a positive step, as MilliporeSigma is a major player in the life science industry.

Stakeholder Impact

• Shareholders should see increased value due to revenue growth and improved profitability.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to improved microbial quality control solutions.
• Suppliers may see increased demand for their products and services.
• Creditors should have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will focus on accelerating system placements.
• The company will focus on improving gross margins.
• The company will focus on innovating new products.
• The company will focus on prudently managing cash.
• The company will work to realize the benefits of the MilliporeSigma collaboration.

Key Dates